THE WHAT? Novo Nordisk has begun broad US distribution of Wegovy capsule, the primary oral GLP-1 remedy authorized for continual weight administration in adults with weight problems or obese with associated medical situations.
THE DETAILS The once-daily oral formulation of semaglutide obtained FDA approval on December 22, 2025 and is now out there via greater than 70,000 US pharmacies, together with CVS and Costco, in addition to chosen telehealth platforms and on-line pharmacy companies.
Scientific information from the Section III OASIS 4 trial confirmed common weight lack of roughly 17 p.c at 64 weeks amongst sufferers who remained on remedy, in contrast with round 3 p.c for placebo. When together with all trial members no matter remedy adherence, common weight reduction was roughly 14 p.c, versus 2 p.c for placebo.
The beginning dose of 1.5 mg is being provided by way of a self-pay programme at US$149 per thirty days, with tiered pricing for increased doses. Novo Nordisk stated the security profile noticed in OASIS 4 was in line with earlier injectable Wegovy trials, with gastrointestinal results among the many mostly reported opposed reactions.
THE WHY? The launch marks a big enlargement of the GLP-1 market past injectable therapies, doubtlessly broadening entry and adoption amongst sufferers reluctant to make use of injections. For client well being, vitamin and beauty-adjacent sectors, the rollout highlights the rising convergence of pharmaceutical weight administration, wellness and long-term way of life intervention, as demand for weight problems remedies accelerates within the US. Elevated availability and decrease entry pricing might additional intensify competitors throughout the quickly increasing weight-loss class.
Supply: Novo Nordisk
